India will be given first priority for the delivery of the AstraZeneca/Oxford vaccine after its British developers claimed success following mass testing, the world’s largest vaccine manufacturer by volume said Monday.
The Chief Executive of the Serum Institute of India, Adar Poonawalla, said the manufacturer has already produced 40 million doses of the vaccine so far. “By January, we should have, you know, 100 million doses is minimum because we’ve already made 40 million doses,” Poonawalla, whose father founded the vaccine manufacturer.
Adar Poonawalla said he expected that some 90 percent of Serum Institute’s doses were to be sold to the Indian government at around 250 rupees. The Serum Institute in August struck a deal with Gavi, the Vaccine Alliance, to produce up to 100 million COVID-19 doses of two different potential vaccines from AstraZeneca and US biotech company Novavax.
Comments are closed, but trackbacks and pingbacks are open.